These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
9. Prevention of uremic bone disease using calcimimetic compounds. Olgaard K; Lewin E Annu Rev Med; 2001; 52():203-20. PubMed ID: 11160775 [TBL] [Abstract][Full Text] [Related]
10. [Calcimimetic agents in the treatment of hyperparathyroidism secondary to chronic renal failure]. Negri AL; Slatopolsky EA Medicina (B Aires); 2003; 63(2):165-71. PubMed ID: 12793088 [TBL] [Abstract][Full Text] [Related]
11. Pharmacological and clinical properties of calcimimetics: calcium receptor activators that afford an innovative approach to controlling hyperparathyroidism. Nagano N Pharmacol Ther; 2006 Mar; 109(3):339-65. PubMed ID: 16102839 [TBL] [Abstract][Full Text] [Related]
12. Future role of calcimimetics in end-stage renal disease. Goodman WG; Turner SA Adv Ren Replace Ther; 2002 Jul; 9(3):200-8. PubMed ID: 12203202 [TBL] [Abstract][Full Text] [Related]
13. Effect of the calcimimetic R-568 [3-(2-chlorophenyl)-N-((1R)-1-(3-methoxyphenyl)ethyl)-1-propanamine] on correcting inactivating mutations in the human calcium-sensing receptor. Lu JY; Yang Y; Gnacadja G; Christopoulos A; Reagan JD J Pharmacol Exp Ther; 2009 Dec; 331(3):775-86. PubMed ID: 19759318 [TBL] [Abstract][Full Text] [Related]
14. [Calcimimmetic and calcilytics: new perspectives of correction of abnormal parathormone (PTH) secretion]. Rybczyńska A; Hoppe A Przegl Lek; 2003; 60(6):418-24. PubMed ID: 14974181 [TBL] [Abstract][Full Text] [Related]
15. Short-term inhibition of parathyroid hormone secretion by a calcium-receptor agonist in patients with primary hyperparathyroidism. Silverberg SJ; Bone HG; Marriott TB; Locker FG; Thys-Jacobs S; Dziem G; Kaatz S; Sanguinetti EL; Bilezikian JP N Engl J Med; 1997 Nov; 337(21):1506-10. PubMed ID: 9366582 [TBL] [Abstract][Full Text] [Related]
16. Calcimimetics with potent and selective activity on the parathyroid calcium receptor. Nemeth EF; Steffey ME; Hammerland LG; Hung BC; Van Wagenen BC; DelMar EG; Balandrin MF Proc Natl Acad Sci U S A; 1998 Mar; 95(7):4040-5. PubMed ID: 9520489 [TBL] [Abstract][Full Text] [Related]
17. The new role of calcimimetics as vasculotropic agents. Al-Aly Z Kidney Int; 2009 Jan; 75(1):9-12. PubMed ID: 19092812 [TBL] [Abstract][Full Text] [Related]
18. [Physiopathology and therapy of primary hyperparathyroidism]. Sugimoto T Nihon Naika Gakkai Zasshi; 1999 Jul; 88(7):1206-11. PubMed ID: 10465965 [No Abstract] [Full Text] [Related]
19. Calcium-sensing receptor and calcimimetic agents. Coburn JW; Elangovan L; Goodman WG; Frazaõ JM Kidney Int Suppl; 1999 Dec; 73():S52-8. PubMed ID: 10633465 [TBL] [Abstract][Full Text] [Related]